Literature DB >> 20013324

Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.

Thomas Meyer1, Volker Ruppert, Christian Görg, Andreas Neubauer.   

Abstract

The somatic V617F mutation in the Janus kinase (JAK) 2 gene, which causes a valine to phenylalanine substitution at position 617, has recently been found in the majority of patients with polycythemia vera and in many cases with essential thrombocythemia or idiopathic myelofibrosis. Here, we report on a 76-year-old female patient presenting with JAK2V617F-positive polycythemia vera and a pelvic mass with extramedullary hematopoiesis. Immunohistochemistry demonstrated tyrosine phosphorylation of JAK2 kinase as well as STAT1 and STAT5 transcription factors. However, only a minority of the total STAT1 pool was tyrosine-phosphorylated and, in contrast to its unphosphorylated counterpart, phospho-STAT1 clearly showed nuclear accumulation. While megakaryotes expressed virtually no phospho-STAT1, phosphorylated STAT5 was mainly restricted to megakaryocytes and rarely detected in non-megakaryocytes. Our data suggest that dysregulated STAT signal pathways are engaged in extramedullary hematopoiesis in polycythemia vera.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013324     DOI: 10.1007/s12185-009-0457-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.

Authors:  Samer Aboudola; Guruanthan Murugesan; Hadrian Szpurka; Giri Ramsingh; Xiaoxian Zhao; Nichole Prescott; Raymond R Tubbs; Jaroslaw P Maciejewski; Eric D Hsi
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.

Authors:  Luciana Teofili; Maurizio Martini; Tonia Cenci; Giovanna Petrucci; Lorenza Torti; Sergio Storti; Francesco Guidi; Giuseppe Leone; Luigi Maria Larocca
Journal:  Blood       Date:  2007-03-21       Impact factor: 22.113

4.  Identification of an acquired JAK2 mutation in polycythemia vera.

Authors:  Runxiang Zhao; Shu Xing; Zhe Li; Xueqi Fu; Qingshan Li; Sanford B Krantz; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

5.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Authors:  Catriona H M Jamieson; Jason Gotlib; Jeffrey A Durocher; Mark P Chao; M Rajan Mariappan; Marla Lay; Carol Jones; James L Zehnder; Stan L Lilleberg; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

6.  Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.

Authors:  K Shide; H K Shimoda; T Kumano; K Karube; T Kameda; K Takenaka; S Oku; H Abe; K S Katayose; Y Kubuki; K Kusumoto; S Hasuike; Y Tahara; K Nagata; T Matsuda; K Ohshima; M Harada; K Shimoda
Journal:  Leukemia       Date:  2007-11-22       Impact factor: 11.528

7.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Authors:  Gerlinde Wernig; Thomas Mercher; Rachel Okabe; Ross L Levine; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

8.  Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

Authors:  Lizz F Grimwade; Lisa Happerfield; Colin Tristram; Gary McIntosh; Mark Rees; Anthony J Bench; Elaine M Boyd; Marie Hall; Amy Quinn; Nigel Piggott; Paul Scorer; Mike A Scott; Wendy N Erber
Journal:  Br J Haematol       Date:  2009-08-31       Impact factor: 6.998

9.  Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

Authors:  Alexandra Dusa; Judith Staerk; Joanne Elliott; Christian Pecquet; Hélène A Poirel; James A Johnston; Stefan N Constantinescu
Journal:  J Biol Chem       Date:  2008-03-06       Impact factor: 5.157

10.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.